Shockingly, there are around 55,200 new breast cancer cases in the UK every year. As such, breast cancer is the most common invasive cancer in women and a leading cause of cancer death. In this exclusive interview, we speak with Richard Bahu, Chair of Trustees at the UK research charity Against Breast Cancer to hear about their vital work.

How did Against Breast Cancer come to fruition?

The total focus of Against Breast Cancer (ABC) is to stop secondary breast cancer from claiming lives. ABC was founded by Dr Anthony Leathem and his wife Patricia. At the time, Anthony was a pathologist at the Middlesex Hospital (later University College London) and his wife Patricia was a breast cancer theatre nurse at Oxford’s Churchill Hospital. They were deeply upset by the number of post-mortems he carried out each day on young women with breast cancer. They had to act by personally fundraising to support his research into breast cancer survival. This included Patricia planting their entire allotment with sweet peas to sell, and Anthony in his white coat outside Oxford Street tube station with a collection tin! Anthony’s research paper describing a difference between aggressive and non-aggressive breast cancer cells was the springboard for setting up ABC in 1993.

How does Against Breast Cancer support research? What types of research do you fund?

Our research strategy is set out in our Roadmap with three key areas: prevention, detection and new therapies. Prevention includes understanding how diet and lifestyle factors affect the risk of cancer recurrence. Detection aims to design better tools for the earlier detection of secondary cancer through biomarker discovery. New therapies aim to exploit the body’s immune system to create more effective treatments.

Our research strategy has created a significant critical mass of world-class researchers at Southampton University. We complement this with seed funding of researchers who have an exciting research idea but insufficient background research to apply for major funding. Often, these seed-funded projects enable them to successfully apply for major follow-on programmes. We are also committed to encouraging and developing young scientists in breast cancer research through a major fellowship programme at Oriel College, Oxford University.

How is the general public involved in your work?

We wouldn’t be where we are today without the involvement and support of the public. We have amazing supporters who help raise funds for our research projects. There are many ways people get involved, from taking part in local and national events, corporate giving, donating bras and clothes, volunteering their time and skills, and providing touching case studies. We are also grateful to those who leave a legacy in their wills. Some major companies and organisations choose ABC as their charity of the year and we work with them to give their staff a positive experience of our charity work. We also have research advocates who are people with experience with breast cancer and who provide valuable input into the types of projects that we fund.

One amazing and extremely moving example is that of Danielle. She was the focal point for a fundraising campaign in which a lock of her hair taken before her treatment was turned into diamond – the world’s most precious stone. At the end of the campaign, the diamond was incorporated into a necklace by a leading designer and donated to her young daughter.

We are, of course, in the midst of the COVID-19 pandemic. What specific difficulties has this brought to the work of Against Breast Cancer?

Clearly, this has had a dramatic effect not just on our fundraising but also on our staff and supporters. Being a smaller charity, we can react quickly to these challenges. Our team has risen to the challenge by being creative in moving activities online and into a virtual world. We have retained all our staff whilst other charities have sadly let many people go. This is a reflection of the lean management of the charity by an outstanding management team. We have also benefited from prudent management of our funds which has enabled us to cope robustly with the financial pressures.

There has been an impact on our research and with our full support, some of our researchers have joined the effort to combat the virus. However, we have been very pleased with how our researchers have sought to move their projects forward wherever possible. Again, we have continued to support all our funded projects and do not envisage cutting back any of them.

What would you say are Against Breast Cancer’s biggest achievements to date?

Reaching our 25th anniversary in 2018 was a big milestone for the charity. We are particularly proud of achieving our Biobank which is a collection of samples and lifestyle data collected from over 3,000 women over a period of 5 years post-cancer diagnosis. This is such a valuable research resource and one of the largest of its kind in the UK. To date, our research funding has now exceeded £7m and we have laboratories located at one of the world’s leading centres researching secondary breast cancer. ABC’s committed funding up to 2028 sees a portfolio of £4.5m with further funding envisaged for seed grants.

Looking now to the future, what are the main challenges and goals for Against Breast Cancer over the next 5–10 years?

ABC is now on a clear path to have a major impact on secondary breast cancer deaths over the next 5–10 years. The biggest challenge is managing the expectations of our supporters as they obviously want quick results whereas the complexity of the research requires a steady and sustained long-term effort to which we are committed. This means we have to provide clear and truthful communication about our research as often people see articles in the press and on social media which talk about breakthroughs but which often are still some way from being implemented in clinical practice.

W: https://www.againstbreastcancer.org.uk/

Twitter: @againstbc

Reference
https://doi.org/10.33548/SCIENTIA642

Want to republish our articles?

 

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Subscribe now!


More articles you may like

Professor Hyun-Joon Ha – Building Diverse Medicinal Compounds from Aziridines

Professor Hyun-Joon Ha – Building Diverse Medicinal Compounds from Aziridines

The artificial synthesis of medicinal compounds that are typically derived from natural sources helps scientists to better understand how they function and deduce whether they can be enhanced. Unfortunately, the work involved in synthesising such natural compounds and their analogues is extremely difficult. Professor Hyun-Joon Ha and his team from Hankuk University of Foreign Studies in the Republic of Korea are exploring ways to transform compounds called aziridines into a range of biologically active molecules.

Dr Jean-Pierre Leburton – Small but Mighty: Game-Changing Nanopore Research

Dr Jean-Pierre Leburton – Small but Mighty: Game-Changing Nanopore Research

The far-reaching benefits of nanopore research encompass fields as diverse as physics, healthcare, big data processing and environmental studies. At the University of Illinois at Urbana-Champaign, Dr Jean-Pierre Leburton is conducting research focused on the use of nanopores in ultrathin solid-state molecular materials, such as graphene and 2D transition-metal dichalcogenides, for DNA sensing applications. This offers a low-cost and highly effective method of identifying biomolecules, and could have widespread medical applications, enabling rapid, early and effective disease diagnosis and prompting effective treatment, as well as providing invaluable technologies for assisting with DNA sequencing.

Professor Maria Ngu-Schwemlein – Developing Mercury Immobilisers and Antibiotic Enhancers

Professor Maria Ngu-Schwemlein – Developing Mercury Immobilisers and Antibiotic Enhancers

The rise of antibiotic-resistant strains of bacteria and the ubiquitous nature of mercury in the environment are two major health hazards and concerns faced today. Professor Maria Ngu-Schwemlein and her team from the Winston-Salem State University, USA, are addressing these issues by developing biomolecules that can bind and immobilise toxic mercury ions more effectively. Together with Professor Ngu-Schwemlein’s collaborators, the team is also investigating carbon nanodots as molecular scaffolds to enhance antibiotics in combating antimicrobial resistance.

Superinsulators: The Hideout of Magnetic Monopoles

Superinsulators: The Hideout of Magnetic Monopoles

Magnetic monopoles have long been dismissed as impossible by many physicists, but their existence has nonetheless been theorised for many decades. Through their extensive research, scientists at Terra Quantum AG, the University of Perugia, and SwissScientific Technologies, show that the end could soon be in sight for this conflict. The team’s investigations into superconducting materials not only show that magnetic monopoles must be real – their discoveries also set the stage for exciting technological advances.